One of its portfolio companies, Xpira Pharmaceuticals, has received approval from the FDA for a Phase 2 psilocybin therapy clinical study for anorexia nervosa, which is a psychedelics industry-focused investment issuer.
There is no approved therapeutic regimen for a deadly disease that affects more women than men and is currently being evaluated by several companies in clinical trial stages.
Origin Therapeutics CEO Alexander Somjen said that the company is committed to safety, efficacy, and clinical expertise as it seeks to become a global leader in the psychedelic treatment of eating disorders. He said that the FDA approval was a major hurdle in the development and potential commercialization of a new treatment for this condition.
The team includes industry professionals in North America and the Netherlands who are experienced in eating disorders, drug development, intellectual property, registration, product commercialization and specialty pharma.